Knowledge Library

Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.

Resource Type: Newsletter
Resource Topic: Candidate Selection Cell-based Assays Hit-to-Lead Immunology Lead Optimization Oncology Tumor Models

VIEW

Faster with high-speed fragment screening — Accelerate your drug discovery campaign

In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited the exploration of this undevelopable area. Today, the combination of novel chemical modalities and advanced technical approaches has resulted in new clinical candidates from previously undruggable targets. To accelerate your drug discovery campaign, WuXi AppTec´s …Read More >

Resource Type: Article Blog Case Study
Resource Topic: Biochemical Assays Biophysical Assays Fragment-Based Drug Discovery Hit Finding Hit-to-Lead Immunology Lead Optimization Small Molecules Structural Biology

VIEW

Antibody and Protein Preparation Services

Integrated Drug Discovery Platform for Antibody & Protein Preparation We are dedicated to offering an integrated and cost-effective services platform of polyclonal and monoclonal antibodies, including: Antigen design and preparation Anti-drug antibodies (ADA) Host cell protein (HCP) antibodies Surrogate antibodies Diagnostic antibodies Therapeutic antibodies Learn about our services platform for evaluating bispecific antibodies

Resource Type: Brochure
Resource Topic: Antibodies Cells and Protein Science Immunology Target Identification and Validation

VIEW

Immuno-Oncology Services

Immuno-oncology Platform An outstanding platform to enable cancer immunotherapy with one stop service: Immunological function assessment TIL analysis – Flowcytometry, Multiplex IF and Cytex Animal models – Syngeneic and humanized models Immune profiling by NGS – Single Cell RNAseq, Mutation burden and TCR/BCR repertoire Clinical biomarker services – CAP certification and GCP compliance

Resource Type: Brochure
Resource Topic: Antibodies Autoimmune and Inflammatory Diseases Biomarkers Cell-based Assays Cells and Protein Science Hit-to-Lead Immunology in vivo Pharmacology Lead Optimization Oncology Phenotypic Assays Target Identification and Validation Target-Specific Assays Tumor Models

VIEW

WuXi Oncology and Immuno-Oncology Services

Integrated Oncology and Immuno-oncology Platform to Enable Translational Science from Drug Discovery to Clinical Biomarker Oncology Services CRISPR/Cas9 Gene Editing In Vitro Assay and HTS Tumor models Tumor Cell Panel and Screening Immunology and Immuno-oncology Platform Clinical Biomarker Immunology Services Ligand-receptor binding assays Cellular functional assays Assays for innate immunity pathways: macrophage, MDSC, NK, DC, …Read More >

Resource Type: Brochure
Resource Topic: Antibodies Biochemical Assays Biomarkers Cell-based Assays Cells and Protein Science Chemical Biology and Proteomics Gene Therapies High-throughput screening (HTS) Hit-to-Lead Immunology in vitro biology in vivo Pharmacology Lead Optimization Oncology Screening Libraries Small Molecules Target Identification and Validation Target-Specific Assays Targeted Protein Degradation Tumor Models

VIEW

Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors

Tumors are complex ecosystems composed of different cell types with different phenotypes, status and gene profiles. Commonly used GEP tools like bulk RNA Sequencing can only display gene expression profiles as a whole, and cannot reflect the heterogeneous tumor cell change or immune composition in a tumor. Single cell RNA sequencing is a good tool …Read More >

Resource Type: Poster
Resource Topic: Immunology Oncology Phenotypic Assays Target Identification and Validation

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!